Just a few years after its founding, AssureRx, a Mason-based a personalized medicine company, has brought on a new president and CEO with more than 30 years of strategic executive experience to grow the company.
James S. Burns was most recently president and CEO of Maryland-based EntreMed Inc., a public clinical-stage pharmaceuticals company that develops cancer and inflammatory disease drug treatments. He’s also managed several science and technology for pharmaceutical, diagnostic and biotech companies. He was a co-founder and president of MedPointe Pharmaceuticals Inc., and founder and managing director of MedPointe Capital Partners, a private equity firm that led the buyout of a New York Stock Exchange company to form MedPointe Pharmaceuticals, among other roles.
“We are thrilled to have a person of Jim’s caliber leading the company into the next phase of its growth. His depth and breadth of experience as CEO of successful early-stage health care companies positions AssureRx for continued leadership in the rapidly expanding field of personalized medicine,” said John C. McIlwraith, chairman of AssureRx and managing director of Blue Chip Venture Co.
The company helps doctors determine the appropriate drug and dosage for each patient’s individual needs.
AssureRx is working to introduce GeneSightRxTM, a lab-developed test that will measure and analyze genetic variants in psychiatric medicine.
“The results of the report can help a doctor understand the way a patient’s unique genetic makeup may affect how certain psychiatric drugs work,” Burns said.
AssureRx was founded in 2006 by through the investment of Queen City Angels, CincyTech, Blue Chip Venture Co., Cincinnati Children’s Hospital Medical Center Tomorrow Fund, Ohio Tech Angels, DHC Tech and private investors. The company was formed to license and commercialize personalized medicine technology research from Cincinnati Children's Hospital Medical Center and Mayo Clinic.
Writer: Feoshia Henderson
Source: Carolyn Pione, communications director CincyTech USA
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.